Comparison · NCT03680092-bec0ddde
Cyclophosphamide and Abatacept vs Methotrexate and Tacrolimus: Occurrence of Moderate and Severe Chronic GVHD at One Year Post Transplant
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Cyclophosphamide and Abatacept vs Methotrexate and Tacrolimus: Occurrence of Moderate and Severe Chronic GVHD at One Year Post Transplant. Trial comparisons, record NCT03680092-bec0ddde. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03680092-bec0ddde
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0 | 0.0000000000000000139 | 0.138 | wilson | |
| Risk in group 2 | 0.571 | 0.326 | 0.786 | wilson | |
| Risk difference, group 1 minus group 2 | -0.571 | -0.786 | -0.29 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | log | a group has no participants with the outcome | |||
| Odds ratio, group 1 over group 2 | log | a cell of the two-by-two table is zero | |||
| Number needed to treat, for one fewer participant with the outcome on Cyclophosphamide and Abatacept than on Methotrexate and Tacrolimus | 1.75 | 1.27 | 3.45 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Cyclophosphamide and Abatacept | The GVHD prophylaxis regimen on the experimental arm will consist of high dose Cyclophosphamide on Days +3 and +4 followed by abatacept for 6 months. Abatacept at a dose of 10mg/kg will be administered on days +5, +14 and +28, +56, +84, +112, +140, +168~Cyclophosphamide: Day 3 and day 4 following transplant. Dosing will be based on patients' actual weight up to 120% of ideal body weight, above which it will be based on adjusted ideal body weight (ideal weight plus 50% of the difference between ideal and actual weight).~abatacept: Abatacept at a dose of 10mg/kg will be administered on days +5, +14 and +28, +56, +84, +112, +140, +168 | 0 | 24 | OG000 |
| Group 2 | Methotrexate and Tacrolimus | The GVHD prophylaxis regimen on the standard of care arm will consist of methotrexate on Days +1,+3, +6 and +11 and tacrolimus~Methotrexate: standard of care Methotrexate 5 mg/m2 on Days 1, 3, 6 and 11~Tacrolimus: Tacrolimus per institutional guidelines | 8 | 14 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Occurrence of Moderate and Severe Chronic GVHD at One Year Post Transplant
- Description
The occurrence of moderate and severe chronic GVHD at one year post Chronic GVHD will be diagnosed and staged according to the previously published and widely accepted National Institutes of Health consensus criteria
- Time frame
- through study completion, an average of 1 year
- Population
Source ClinicalTrials.gov
Trial
- Title
- Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation
- NCT number
- NCT03680092
- Phases
- PHASE2
- Conditions
- GVHD, Hematologic Neoplasms
- Interventions
- Cyclophosphamide, abatacept, Methotrexate, Tacrolimus
- Lead sponsor
- Dimitrios Tzachanis, MD PhD
- Results first posted
- 2024-10-02
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03680092?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03680092-bec0ddde